University of Arkansas

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Arkansas sits in the top decile of US sponsors by registered trial count (#113 of 15,742 sponsors by registered trial count).

318 total trials 37 currently recruiting 202 completed early-phase tilt top decile by trial count

University of Arkansas: 318 sponsored US clinical trials, 37 recruiting.

University of Arkansas sponsors 318 registered US clinical trials on ClinicalTrials.gov, 37 of them currently recruiting, and 202 completed. 17 of these trials are in Phase 3-4 (later-stage) and 102 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Multiple Myeloma, with 15 trials.

Top-decile sponsor footprint

University of Arkansas ranks in the top decile of sponsors by registered trial count (#113 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 32/100

202 of 262 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (77.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

318 total, page 4 of 7

COMPLETED NA

A Physical Activity Program in End-state Liver Disease

NCT02776553

COMPLETED NA

Reducing Depressive Symptoms Among Rural African Americans

NCT02860741

TERMINATED Phase 4

Bupropion for Depression in ESRD Patients on Hemodialysis

NCT02238977

COMPLETED Phase 2

Motivated Behavior in Adults With and Without ADHD

NCT02630017

COMPLETED Phase 2

Improving Treatment Outcomes for Prescription Opioid Dependence

NCT02543944

COMPLETED NA

Neuropathic Pain in Pregnancy

NCT02608463

TERMINATED NA

Pilot Study: Rectus Sheath Blocks for Improving Abdominal Surgery Conditions

NCT02447965

COMPLETED Phase 2

A Clinical Trial of PepCan to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions

NCT02481414

COMPLETED Phase 2

UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment

NCT02499081

COMPLETED NA

Real-time fMRI and Neurofeedback of Brain Networks Mediating Trauma Memory Recall in PTSD

NCT02500719

COMPLETED NA

A Pilot Study to Assess the Immunogenicity of Candidate PSA Peptides for a Prostate Cancer Vaccine

NCT02485964

COMPLETED

Relationship Between HbA1c and Chronic Glycemia in Patients With Cirrhosis

NCT02389127

TERMINATED Early Phase 1

Study Evaluating Sphenopalatine Ganglion Block (SPGB) for Treatment of Postdural Puncture Headache (PDPH)

NCT02365909

COMPLETED NA

Family Model of Diabetes Self-Management Education in the Marshallese Community

NCT02407132

COMPLETED Phase 2

UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus

NCT02192775

COMPLETED Phase 1

Vaccination of High Risk Breast Cancer Patients

NCT02229084

COMPLETED Early Phase 1

Efficacy of Fluorescein Visualization of the Uterus in Detecting Endometrial Cancer Invasion

NCT01979003

TERMINATED Early Phase 1

A Pilot Study Assessing the Effect of Lymphaticovenous Micro-Anastomosis in the Treatment of Postmastectomy Lymphedema

NCT02020837

TERMINATED NA

The Effects of ProFoveate on Reducing Self-Stimulating Behaviors

NCT02088047

TERMINATED Phase 2

UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

NCT02128230

COMPLETED

MR Imaging Biomarkers of Disease Response to ECT (Electroconvulsive Therapy) in Depression

NCT02044289

TERMINATED Phase 2

Glutamine for the Prevention of Radiation Toxicity in Subjects Conserving Therapy

NCT02012608

COMPLETED NA

Implementation Trial of Evidence Based Practices for Mood Disorders

NCT02150577

COMPLETED Phase 1

Clinical Efficacy of Lisdexamfetamine for Methamphetamine Dependence

NCT02034201

TERMINATED

Evaluation of a Microendoscopic Imaging System in Examination of Resected Tissues

NCT01968863

TERMINATED Early Phase 1

Is a Smartphone Application Effective as an Oral Medication Adherence Aid

NCT01968876

COMPLETED

Observational Study Evaluating the Potential Impact of Procalcitonin Testing on Care of Stemcell Transplant Recipients

NCT02035189

COMPLETED Phase 1

Improving Buprenorphine Detoxification Outcomes With Isradipine

NCT01895270

COMPLETED Phase 2

A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women

NCT01877564

TERMINATED

Glutamine Challenge as Predictor of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS)

NCT02026609

COMPLETED Phase 2

UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma

NCT01884688

COMPLETED NA

Transcranial Direct Current Stimulation for Improving Gait Training in Stroke

NCT01807637

COMPLETED NA

Does Noninvasive Electrical Stimulation of Acupuncture Points (NESAP) Reduce Heelstick Pain in Infants?

NCT01800318

TERMINATED NA

Sutures vs. Staples Skin Closure After C-section in Obese Patients

NCT01820221

COMPLETED NA

Does Alkalinization Reduce Perceived Pain Levels During Sentinel Lymph Node Imaging?

NCT01660412

COMPLETED Phase 1

A Phase I Clinical Trial of an HPV Therapeutic Vaccine

NCT01653249

TERMINATED Phase 2

Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth

NCT01632020

COMPLETED

Assessment of Fat Free Mass Index and Its Impact on Health in Children With Cystic Fibrosis

NCT01401439

COMPLETED NA

Effect of Repetitive Transcranial Magnetic Stimulation on Resting State Brain Activity in Schizophrenia

NCT01620086

COMPLETED NA

Weight Loss and Maintenance for Rural, African American Communities of Faith (The WORD)

NCT02169947

COMPLETED

Mitochondrial Dysfunction in Phelan-McDermid Syndrome

NCT02000167

COMPLETED

Etiology and Early Diagnosis of Neurodevelopmental Disorders

NCT02003170

COMPLETED

Improving Anticoagulant Therapy Through Warfarin Metabolite Profiling

NCT01964794

TERMINATED Phase 2

A Folinic Acid Intervention for Autism Spectrum Disorders

NCT01602016

COMPLETED Phase 1

Walnut Oral Immunotherapy for Tree Nut Allergy

NCT01546753

COMPLETED Phase 1

Clinical Efficacy of Atomoxetine for Methamphetamine Dependence

NCT01557569

COMPLETED NA

A Lifestyle Physical Activity Intervention for Older Sedentary Women

NCT01707693

TERMINATED NA

Study of Hyperbaric Oxygen Therapy in Addition to Standard Growth Factor Support for Hematopoietic Progenitor/Stem Cell Mobilization

NCT01449539

TERMINATED Phase 2

Hydroxychloroquine in Cardiovascular Disease in Patients With Chronic Kidney Disease: A Proof of Concept Study

NCT01537315

COMPLETED NA

Safety of Noninvasive Electrical Stimulation of Acupuncture Points (NESAP) in Infants

NCT01495286

← Previous Page 4 of 7 Next →

Phase Distribution

PhaseTrial count
Phase 1 40
Phase 2 62
Phase 3 13
Phase 4 4

What is open in the University of Arkansas pipeline

37 recruiting of 318 indexed (12% open); 202 completed (64%).

Phase mix: 17 late (III/IV) vs 102 early (I/II) (early-phase heavy).

Top condition: Multiple Myeloma (15 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Arkansas: open-pipeline peers nationwide

Peers matched on 318 registered trials and 12% open enrollment, not the therapeutic-area sidebar.

University of Arkansas sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400 0%5%10%15%20% Total trials Recruiting share University of ArkansasRush University Medical CenterJonsson Comprehensive Cancer CenterAllerganCelgeneJazz PharmaceuticalsAbbott Diabetes CareMedtronic VascularMidwest Center for Metabolic and Cardiovascular Research
University of Arkansas sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Arkansas sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 318 trials (± recruiting share)

Sponsors near 12% open enrollment (± trial volume)

What to do with this University of Arkansas page

318 registered trials is a research-attention snapshot, not an endorsement of University of Arkansas or any single study.

  • 37 of University of Arkansas's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Multiple Myeloma is the condition University of Arkansas studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Multiple Myeloma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

University of Arkansas pipeline card: 318 registered trials from official public datasets.Report a data error.